SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Akero Therapeutics, Inc. (AKRO) , 前瞻盈利收益率 1.46%.
本页证实的标准:
- VALUE (20/100, 未通过) — 分析师共识目标价暗示当前价格存在下行风险 ($46.00, 15.8%).
- 前瞻市盈率 68.3
- 分析师共识目标价 $46.00 (-15.8% 下行风险) — 分析师认为当前价格水平存在明显下行风险。
SharesGrow 综合评分： 36/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
✗
价值
20/100
Price-to-Earnings & upside
Proven by this page
✓
健康
100/100
Debt-to-Equity & liquidity
→ Health
估值概览 — AKRO
估值倍数
P/E (TTM)0.0
前瞻 P/E68.3
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.00
EV/EBITDA0.0
每股数据
EPS (TTM)$-3.75
前瞻 EPS（预估）$0.80
每股账面价值$0.00
每股营收$0.00
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
Forward Earnings Yield1.46%
股息收益率0.00%
分析师目标价$46.00 (-15.8%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2017 |
$-0.16 |
$0.00 |
$-4.56M |
- |
| 2018 |
$-3.85 |
$0.00 |
$-81.71M |
- |
| 2019 |
$-2.90 |
$0.00 |
$-43.76M |
- |
| 2020 |
$-2.52 |
$0.00 |
$-79.19M |
- |
| 2021 |
$-2.89 |
$0.00 |
$-100.74M |
- |
| 2022 |
$-2.79 |
$0.00 |
$-108.91M |
- |
| 2023 |
$-2.89 |
$0.00 |
$-151.76M |
- |
| 2024 |
$-3.75 |
$0.00 |
$-252.06M |
- |
